Dose constraints for moderate hypofractionated radiotherapy for prostate cancer The French genito-urinary group (GETUG) recommendations

Abstract : Considering recent phase III trials results, moderate hypofractionated radiotherapy can be considered as a standard treatment for low and intermediate risk prostate cancer management. This assessment call for a framework allowing homogeneous and reproducible practices in the different centers using this radiotherapy schedule. The French Genito-Urinary Group (GETUG) provides here recommendations for daily practice of moderate hypofractionated radiotherapy for prostate cancer, with indications, dose, fractionation, pre-treatment planning, volume of interest delineation (target volume and organs at risk) and margins, dose constraints and radiotherapy techniques.
Document type :
Journal articles
Complete list of metadatas

https://hal-univ-rennes1.archives-ouvertes.fr/hal-01807361
Contributor : Laurent Jonchère <>
Submitted on : Monday, June 4, 2018 - 4:27:20 PM
Last modification on : Friday, November 30, 2018 - 2:06:42 PM

Identifiers

Citation

J Langrand-Escure, R de Crevoisier, C Llagostera, G Créhange, G Delaroche, et al.. Dose constraints for moderate hypofractionated radiotherapy for prostate cancer The French genito-urinary group (GETUG) recommendations. Cancer Radiothérapie, Elsevier Masson, 2018, 22 (2), pp.193-198. ⟨10.1016/j.canrad.2017.11.004⟩. ⟨hal-01807361⟩

Share

Metrics

Record views

66